复星医药
(600196)
| 流通市值：506.11亿 | | | 总市值：637.97亿 |
| 流通股本：21.18亿 | | | 总股本：26.70亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 20,441,970,386 | 10,073,223,477.03 | 41,661,612,748.15 | 29,393,385,360.91 |
| 营业总成本 | 19,682,627,988.3 | 9,532,295,160.5 | 40,087,325,053.49 | 28,415,595,587.6 |
| 其他经营收益 | | | | |
| 营业利润 | 2,615,941,075.38 | 1,375,376,200.03 | 5,228,351,339.59 | 3,906,765,379.57 |
| 利润总额 | 2,586,571,906.93 | 1,357,544,436.17 | 5,111,983,263.87 | 3,837,343,481.79 |
| 净利润 | 2,148,928,430.32 | 1,079,627,854.14 | 4,247,929,628.38 | 3,056,091,951.68 |
| 每股收益 | | | | |
| 其他综合收益 | -913,684,904.03 | -616,755,016.63 | -675,759,872.93 | -385,229,723.22 |
| 综合收益总额 | 1,235,243,526.29 | 462,872,837.51 | 3,572,169,755.45 | 2,670,862,228.46 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 34,799,347,678.29 | 33,964,684,348.73 | 33,820,671,330.27 | 32,145,481,005.88 |
| 非流动资产: | | | | |
| 非流动资产合计 | 90,628,555,416.56 | 89,001,703,917.37 | 86,233,297,595.78 | 85,975,257,507.13 |
| 资产总计 | 125,427,903,094.85 | 122,966,388,266.1 | 120,053,968,926.05 | 118,120,738,513.01 |
| 流动负债: | | | | |
| 流动负债合计 | 38,595,926,544.58 | 36,580,714,242.42 | 36,424,316,078.84 | 35,086,945,012.22 |
| 非流动负债: | | | | |
| 非流动负债合计 | 23,430,053,586.74 | 22,716,324,968.36 | 21,789,302,995.87 | 22,222,193,608.32 |
| 负债合计 | 62,025,980,131.32 | 59,297,039,210.78 | 58,213,619,074.71 | 57,309,138,620.54 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 48,731,193,493.03 | 49,146,744,750.46 | 48,741,507,004.7 | 48,028,502,901.05 |
| 股东权益合计 | 63,401,922,963.53 | 63,669,349,055.32 | 61,840,349,851.34 | 60,811,599,892.47 |
| 负债和股东权益合计 | 125,427,903,094.85 | 122,966,388,266.1 | 120,053,968,926.05 | 118,120,738,513.01 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 21,969,649,537.43 | 11,104,892,656.89 | 43,315,418,661.34 | 32,212,081,100.74 |
| 经营活动现金流出小计 | 19,545,697,122.75 | 9,956,294,869.07 | 38,102,191,782.99 | 28,830,312,535.03 |
| 经营活动产生的现金流量净额 | 2,423,952,414.68 | 1,148,597,787.82 | 5,213,226,878.35 | 3,381,768,565.71 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 907,292,950.29 | 590,290,272.15 | 3,722,258,666.04 | 2,888,011,838.78 |
| 投资活动现金流出小计 | 5,335,391,260.84 | 2,319,574,775.55 | 5,868,024,954.77 | 4,399,844,279.57 |
| 投资活动产生的现金流量净额 | -4,428,098,310.55 | -1,729,284,503.4 | -2,145,766,288.73 | -1,511,832,440.79 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 13,929,238,711.21 | 7,953,358,102.47 | 37,334,019,380.15 | 26,869,314,775.66 |
| 筹资活动现金流出小计 | 11,253,234,699.24 | 6,675,162,903.95 | 40,578,108,887.3 | 30,113,741,396.85 |
| 筹资活动产生的现金流量净额 | 2,676,004,011.97 | 1,278,195,198.52 | -3,244,089,507.15 | -3,244,426,621.19 |
| 汇率变动对现金及现金等价物的影响 | -222,600,992.35 | -158,570,564.25 | -176,810,748.88 | -80,826,833.37 |
| 现金及现金等价物净增加额 | 449,257,123.75 | 538,937,918.69 | -353,439,666.41 | -1,455,317,329.64 |
| 期末现金及现金等价物余额 | 9,487,267,244.45 | 9,576,948,039.39 | 9,038,010,120.7 | 7,936,132,457.47 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 449,257,123.75 | - | -353,439,666.41 | - |
最新报告期：2026-09-24| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 浙商证券 | 郭双喜 | 1.42 | 1.72 | 1.92 | 2026-09-24 |
| 中国银河 | 程培,宋丽莹 | 1.36 | 1.56 | 1.73 | 2026-08-28 |